github link
Accession IconGSE19567

Imatinib and Nilotinib induced molecular changes in Philadelphia chromosome-positive Chronic Myelogenous Leukemia

Organism Icon Homo sapiens
Sample Icon 12 Downloadable Samples
Technology Badge Icon Affymetrix Human Genome U133A 2.0 Array (hgu133a2)

Submitter Supplied Information

Description
Chronic myelogenous leukemia (CML) is a malignant stem cell disease characterized by a reciprocal translocation between chromosome 9 and 22. The selective bcr-abl tyrosine-kinase inhibitor Imatinib has become the therapy of choice for patients with newly diagnosed CML including those previously considered candidates for allogeneic haematopoietic stem cell transplantation. The tyrosine-kinase inhibitor Nilotinib is a derivate of Imatinib with higher potency.
PubMed ID
No associated PubMed ID
Publication Title
No associated publication
Total Samples
12
Submitter’s Institution
Authors
No associated authors

Samples

Show of 0 Total Samples
Filter
Add/Remove
Accession Code
Title
Cell line
Treatment
Processing Information
Additional Metadata
No rows found
Loading...